Sofinnova Partners is a European venture capital firm focused on life sciences, healthcare, and sustainability. Based in Paris, London, and Milan, the firm manages over €4bn and has backed more than 500 companies since 1972.
Portfolio
7
companies
AUM
£4.0B
under management
Forth Therapeutics
Forth Therapeutics develops next-generation precision treatments for fibrosis.
Latent Labs
Latent Labs builds AI foundation models to make biology programmable.
Purespring Therapeutics
Purespring Therapeutics develops adeno-associated viral gene therapies for renal diseases.
Sphere Fluidics
Sphere Fluidics develops single cell analysis and characterisation systems for biopharmaceutical discovery.
Synthace
Synthace provides a cloud platform that enables life scientists to automate experiments and share insights.
T-Therapeutics
Developer of next-generation T cell receptor therapeutics for oncology and immunology.
Tom Burt
Partner
Tom brings extensive life sciences investment and equity experience, having previously held roles at Triton Partners, Sofinnova Partners, and Peel Hunt.
LinkedIn
Thomas Burt
Partner
Thomas brings extensive life sciences investment experience from roles at Triton Partners, Sofinnova Partners, and Peel Hunt. He previously held positions at Ares Life Sciences, Novo A/S, and Piper Jaffray.
Graziano Seghezzi
Managing Partner
Graziano is Managing Partner at Sofinnova Partners. He previously held investment roles at Index Ventures and Sofinnova Partners, following postdoctoral research at NYU Langone Medical Center.
LinkedInEdward Kliphuis
Partner
Edward serves as a partner at Sofinnova Partners and holds board seats at several organisations including Excelsior Sciences, Latent Labs, Bioptimus, and l'ecole AI.
LinkedInMaina Bhaman
Partner
BGF and Tencent join existing shareholders to support the biotechnology company in advancing its drug development programmes.
"We are delighted to have significantly added to our Series A financing, which we see as a strong validation of both our technology and our progress to date. I would like to thank Tencent and BGF for their belief in our potential, as well as all our existing investors for their continued support."
The financing from Sofinnova Partners and Old College Capital will support the launch of precision fibrosis therapeutics.
"Launching Forth Tx through Sofinnova’s biotech accelerator has allowed us to translate years of our multiomics-driven research into precision therapies that we hope will transform patients’ lives. Fibrosis is an area of huge unmet medical need, and I’m delighted to be working with Alex and the Sofinnova team, as well as OCC, to deliver potent, new treatments for patients with fibrosis."
The financing round was co-led by Radical Ventures and Sofinnova Partners to accelerate the development of programmable biology tools.
"Every biotechnology or pharmaceutical company wants to be at the forefront of technology to find the best therapeutic molecules, yet not all are in a position to develop the most advanced AI models for the job. That’s where Latent Labs comes in. We push the frontiers of generative biology, giving our partners instant access to tools that accelerate their drug design programs."
The financing round was led by Sofinnova Partners and will fund upcoming clinical trials for kidney disease treatments.
"Our investment into Purespring Therapeutics fits perfectly into our strategy to support the UK’s life sciences and is the type of UK growth company which could benefit further by unlocking the potential of institutional investment. We need to support companies like Purespring as they go through development and trials before coming to market.Providing that capital simultaneously stimulates growth and helps to solve pressing medical challenges that will deliver long-term outcomes for generations to come."
The financing round was led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital.
"We’re delighted to have raised this Series A with such high-quality investors whose amazing networks and shared vision will help us deliver highly differentiated TCR cancer therapies. TCR therapeutics are very much at the dawn of their potential. We intend to replicate the success of therapeutic antibodies but build on this in a new dimension, by using the targeting domains of TCR receptors to take advantage of their much greater specificity for cancer cells compared to normal cells. The same logic can be used to target immunosuppressive biologics to tissues impacted by autoimmune disorders."
